Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIRDIE trial
NL-OMON60194Phase 3Recruiting
- Sponsor
- Franciscus Gasthuis & Vlietland
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of dupilumab and mepolizumab, sponsored by Franciscus Gasthuis & Vlietland. Started Feb 2024; status: recruiting.
02
Drugs
dupilumabmepolizumab
Beyond the preview
Go deeper on NL-OMON60194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60194.